Gaspar H B, Ferrando M, Caragol I, Hernandez M, Bertran J M, De Gracia X, Lester T, Kinnon C, Ashton E, Espanol T
Molecular Immunology Unit, Institute of Child Health, University College London, London, UK.
Clin Exp Immunol. 2000 May;120(2):346-50. doi: 10.1046/j.1365-2249.2000.01230.x.
X-linked agammaglobulinaemia (XLA) is a B cell humoral abnormality arising from mutations in the gene encoding Bruton's tyrosine kinase (Btk). The phenotype of XLA can be variable, with some individuals having a less severe immunophenotype, although in most cases this cannot be correlated with the Btk mutation or expression of Btk protein. In this study we describe clinical and immunological heterogeneity within the same pedigree. Analysis of the genetic defect identified a missense mutation in the kinase domain of Btk which, unusually, preserved Btk protein expression but at reduced levels, and also considerably diminished autophosphorylation activity. Structural analysis of the effect of this mutation on the kinase domain suggests that this mutation is not an integral part of the ATP or substrate binding domains but may affect the interaction of the kinase domain with its own kinase domain and other substrates. Together, these data may provide an explanation for the variable XLA phenotype.
X连锁无丙种球蛋白血症(XLA)是一种B细胞体液异常疾病,由编码布鲁顿酪氨酸激酶(Btk)的基因突变引起。XLA的表型可能存在差异,一些个体的免疫表型较轻,尽管在大多数情况下,这与Btk突变或Btk蛋白表达无关。在本研究中,我们描述了同一谱系内的临床和免疫异质性。对遗传缺陷的分析确定了Btk激酶结构域中的一个错义突变,不同寻常的是,该突变保留了Btk蛋白表达,但水平降低,并且还显著降低了自身磷酸化活性。对该突变对激酶结构域影响的结构分析表明,此突变不是ATP或底物结合结构域的组成部分,但可能影响激酶结构域与其自身激酶结构域及其他底物的相互作用。这些数据共同可能为XLA表型的变异性提供一种解释。